K Lea Sewell Selected Research

Adalimumab (Humira)

1/2018

A comparative clinical study of PF-06410293, a candidate adalimumab biosimilar, and adalimumab reference product (Humira®) in the treatment of active rheumatoid arthritis.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

K Lea Sewell Research Topics

Disease

3	Rheumatoid Arthritis 01/2018 - 01/2018
1	Injection Site Reaction 01/2018
1	Hypersensitivity (Allergy) 01/2018
1	Myocardial Infarction 01/2018
1	Opportunistic Infections (Opportunistic Infection) 01/2018
1	Pneumonia (Pneumonitis) 01/2018
1	Rheumatic Diseases (Rheumatism) 01/2018
1	Proteinuria 08/2010
1	Albuminuria 08/2010
1	Diabetic Nephropathies (Diabetic Nephropathy) 08/2010
1	Crohn Disease (Crohn's Disease) 02/2003
1	Body Weight (Weight, Body) 02/2003

Drug/Important Bio-Agent (IBA)

3	Biosimilar PharmaceuticalsIBA 01/2018 - 01/2018
2	Methotrexate (Mexate)FDA LinkGeneric 01/2018 - 01/2018
1	Rituximab (Mabthera)FDA Link 01/2018
1	Infliximab (Remicade)FDA Link 01/2018
1	PF-06410293IBA 01/2018
1	Adalimumab (Humira)FDA Link 01/2018
1	C-Reactive ProteinIBA 01/2018
1	GP1111IBA 01/2018
1	pamrevlumabIBA 08/2010
1	Proteins (Proteins, Gene)FDA Link 08/2010
1	Monoclonal AntibodiesIBA 08/2010
1	Connective Tissue Growth FactorIBA 08/2010
1	Therapeutic UsesIBA 08/2010
1	alicaforsenIBA 02/2003
1	OligonucleotidesIBA 02/2003
1	Intercellular Adhesion Molecule-1 (Intercellular Adhesion Molecule 1)IBA 02/2003
1	Messenger RNA (mRNA)IBA 02/2003

Therapy/Procedure

1	Therapeutics 01/2018